期刊文献+

ER、PR、p53和Bcl-2的表达变化在乳腺癌新辅助化疗中的意义 被引量:8

Significance of expression changes of ER,PR,p53 and Bcl-2 induced by neoadjuvant chemotherapy(NAC) in breast cancer
下载PDF
导出
摘要 目的:回顾性探讨乳腺癌组织中ER、PR、p53及Bcl-2表达变化在新辅助化疗(neoadjuvant chemo-therapy,NAC)中的意义,指导乳腺癌化疗的选择及判断预后。方法:术前采用空心针穿刺活检予以病理确诊并行ER、PR、p53及Bcl-2测定。化疗采用CEF方案[氟尿嘧啶(flurouracil,5-FU)500mg/m2,表柔比星(epirubicin,EPI)75mg/m2,环磷酰胺(cyclophosphamide,CTX)500mg/m2],经3个疗程化疗,再行乳腺癌改良根治术或保乳手术,免疫组化SP法检测98例Ⅱ/Ⅲ期乳腺癌病例在疗前后乳腺癌组织中ER、PR、p53及Bcl-2的表达,比较化疗前后上述各指标阳性表达率的变化。结果:98例Ⅱ/Ⅲ期乳腺癌患者经3个周期新辅助化疗后,70例(71.4%)获得临床部分缓解。化疗前后ER、PR阳性表达率均无显著变化(P>0.05);p53及Bcl-2化疗前后表达阳性率显著变化(P<0.05),化疗有效组中p53蛋白阳性表达率显著下降(P<0.05)而Bcl-2阳性表达率显著上升(P<0.05)。结论:ER、PR表达在新辅助化疗前后无显著差异,新辅助化疗可能通过抑制p53的表达来抑制乳腺癌的增殖并通过上调Bcl-2表达来调整肿瘤细胞分化。 Objective:To retrospectively investigate the impact of neoadjuvant chemotherapy on the expressions of ER,PR,p53 and Bcl-2 to guide the choice of treatment and predict prognosis.Methods: The diagnosis was proved by core biopsy before operation.The expressions of ER,PR,p53 and Bcl-2 before and after operation were measured by immunohistochemical staining method in 98 patients.All the patients received 3 cycles of CEF chemotherapy regimen [fluorouracil(5-FU) 500 mg/m2,epirubicin(EPI) 75 mg/m2,cyclophosphamide(CTX) 500 mg/m2],after 3 cycles of chemotherapy modified radical mastectomy or breast-conserving surgery was performed and the ER,PR,p53 and Bcl-2 expression was measured again.To compare the positive expression before and after neoadjuvant chemotherapy.Results: In 98 patients with Ⅱ /Ⅲ breast cancer patients after 3 cycles of neoadjuvant chemotherapy,70 patients(71.4%) obtained a clinical partial remission.Before and after chemotherapy positive expression of ER,PR did not change significantly(P0.05);p53 and Bcl-2 expressions significantly changed before and after chemotherapy(P0.05).With the increasing efficacy of chemotherapy significantly the expression of p53 significantly downregulated(P0.05),but the expression of Bcl-2 significantly upregulated(P0.05).Conclusion: The expressions of ER,PR were no significant difference before and after NAC,but NAC may suppress the expression of p53 to inhibit the tumor growth and adjust the differentiation of tumor cell through upregulating expression of Bcl2.
出处 《现代肿瘤医学》 CAS 2011年第10期2017-2020,共4页 Journal of Modern Oncology
基金 安徽省卫生厅自然科学基金资助项目(编号:09C230)
关键词 乳腺癌 新辅助化疗(NAC) 雌激素受体 孕激素受体 P53 Bcl-2 breast cancer neoadjuvant chemotherapy(NAC) ER PR p53 Bcl-2
  • 相关文献

参考文献11

  • 1Tiezzi DG,Andrade JM,Ribeiro-Silva A,et al.HER-2,p53,p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination[J].BMC Cancer,2007,7(2):36-46.
  • 2Lee SH,Chung MA,Quddus MR,et al.The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancer[J].Am J Surg,2003,186(4):348-350.
  • 3费伯健,周士福,金留根,林奇.新辅助化疗对乳腺癌激素受体表达和状态的影响[J].南京医科大学学报(自然科学版),2005,25(11):772-774. 被引量:18
  • 4Taucher S,Rudas M,Gnant M,et al.Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy[J].Endocr Relat Cancer,2003,10(1):91-98.
  • 5T Hiratal,C Shimizu,K Yonemori,et al.Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impacton the long-term outcome in patients with primary breast cancer[J].Br J Cancer,2009,101(5):1529-1536.
  • 6Poelman SM,Heimann R,Fleming GF,et al.Invariant p53 immunostaining in primary and recurrent breast cancer[J].Eur J Cancer,2004,40(1):28-32.
  • 7Warnberg F,Nordgren H,Bergkvist L,et al.Tumor markers in breast carcinoma correlate with grade rather than invasiveness[J].Br J Cancer,2001,85(6):869.
  • 8Callagy GM,Pharoah PD,Pinder SE,et al.Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index[J].Clin Cancer Res,2006,12(8):2468-2475.
  • 9Nadler Y,Camp RL,Giltnane JM,et al.Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer[J].Breast Cancer Res,2008,10(2):35.
  • 10李永清,王永胜,刘延冰,赵桐,李济宇,陈鹏.新辅助化疗对乳腺癌bcl-2、bax基因表达影响的研究[J].实用癌症杂志,2006,21(3):263-265. 被引量:4

二级参考文献27

  • 1徐光炜.中国常见恶性肿瘤诊治规范(第八分册).乳腺癌[M].北京医科大学中国协和医科大学联合出版社,1991.53-53.
  • 2Kajiwara M,J Surg Oncol,1999年,70卷,4期,209页
  • 3Zhang G J,Anticancer Res B,1998年,18卷,3期,1989页
  • 4Shen K L,Cancer,1998年,82卷,2373页
  • 5Todd D,Human Pathology,1996年,27卷,1012页
  • 6Peng H Q,Cancer Res,1995年,53卷,3574页
  • 7Xia F,Cancer Res,1995年,55卷,12页
  • 8Lu P J,J Cell Biol,1995年,129卷,1363页
  • 9Shi L,Science,1994年,1143页
  • 10徐光炜,中国常见恶性肿瘤诊治规范.8.分册乳腺癌,1991年,53页

共引文献37

同被引文献93

引证文献8

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部